USANA Health Sciences, Inc. revised earnings guidance for the year 2023. The company narrows fiscal year 2023 net sales and diluted EPS outlook to $900 million to $920 million and $2.80 to $3.05, respectively (previously $900 million to $950 million and $2.65 to $3.30).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.47 USD | +0.76% | -1.50% | -18.90% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.90% | 836M | |
+8.20% | 7.78B | |
+0.34% | 7.38B | |
+10.20% | 6.52B | |
-8.10% | 3.67B | |
-13.13% | 3.44B | |
-14.57% | 1.17B | |
+8.34% | 934M | |
-42.27% | 879M | |
+0.32% | 711M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- USANA Health Sciences, Inc. Revises Earnings Guidance for the Year 2023